Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBI-888 in Advanced Solid Tumors
NCT03573544Phase 2Terminated
- Sponsor
- OBI Pharma
- Start
- May 2018
- Primary completion
- Apr 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of OBI-888 in solid tumor, sponsored by OBI Pharma. Started May 2018; status: terminated.
02
Drugs
OBI-888
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03573544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573544.